CN101104631A - Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram - Google Patents

Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram Download PDF

Info

Publication number
CN101104631A
CN101104631A CNA2007100435179A CN200710043517A CN101104631A CN 101104631 A CN101104631 A CN 101104631A CN A2007100435179 A CNA2007100435179 A CN A2007100435179A CN 200710043517 A CN200710043517 A CN 200710043517A CN 101104631 A CN101104631 A CN 101104631A
Authority
CN
China
Prior art keywords
erythromycin
berythromycin
ethyl acetate
solvent system
methyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CNA2007100435179A
Other languages
Chinese (zh)
Other versions
CN100509835C (en
Inventor
朱家文
陈琪
陈葵
武斌
纪利俊
王维娜
符晓晖
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI TONGTIAN BIOTECHNOLOGY CO Ltd
East China University of Science and Technology
Original Assignee
SHANGHAI TONGTIAN BIOTECHNOLOGY CO Ltd
East China University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI TONGTIAN BIOTECHNOLOGY CO Ltd, East China University of Science and Technology filed Critical SHANGHAI TONGTIAN BIOTECHNOLOGY CO Ltd
Priority to CNB2007100435179A priority Critical patent/CN100509835C/en
Publication of CN101104631A publication Critical patent/CN101104631A/en
Application granted granted Critical
Publication of CN100509835C publication Critical patent/CN100509835C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Saccharide Compounds (AREA)

Abstract

The invention relates to a method for prepararing highly purified erythromycin A, erythromycin B, and erythromycin C simultaneously or separately from erythromycin raw material with high-speed countercurrent chromatography, comprising that a solvent system composed of stationary phases and mobile phases is prepared, the stationary phases are filled in a countercurrent chromatograph column, and then the mobile phases are pumped into the column. The raw material containing components of the erythromycin A, B, C is dissolved in lower phase solvent. Sample is injected through a sample injection valve, component peaks of the erythromycin A, the erythromycin B, and the erythromycin C are respectively received according to a UV atlas of a detector. The solvent system is composed of n-hexane, ethyl acetate, methanol and water, the amount and volume ratio is 0.5-1.3: 0.5-2.0: 2.0-1. The method is characterized in high efficient and fast separation, large quantity of separation amount, no lost of the sample, high recovery rate, mild separation environment and solvent saving.

Description

High speed adverse current chromatogram prepares the method for Erythromycin A, berythromycin, Erythromycin C
Technical field
The present invention relates to a kind of method that from the erythromycin raw material, prepares high purity Erythromycin A, berythromycin, Erythromycin C, particularly relate to a kind of method that adopts high speed adverse current chromatogram to prepare high purity Erythromycin A, berythromycin, Erythromycin C.
Background technology
Erythromycin (Erythromycin is called for short EM) is a kind of Macrolide Broad spectrum antibiotics.The present known six kinds of isomer that wherein have are respectively Erythromycin A, B, and C, D, E and F, A are main active ingredient.The physico-chemical property of berythromycin and Erythromycin C and antimicrobial spectrum are similar to Erythromycin A, but their anti-microbial activity generally has only 30%~60% of Erythromycin A.Therefore, the major part of using in the medical treatment at present is an Erythromycin A.
The sample of highly purified erythromycin component all has crucial meaning for the research work of various relevant erythromycin.
The similar performance of Erythromycin A and berythromycin, Erythromycin C, general separation means are difficult to it is separated.High speed adverse current chromatogram (High Speed Counter Current Chromatography, HSCCC) be a kind of efficient liquid liquid distribution chromatography isolation technique that need not the solid support thing of releasing in 1980, successfully apply to fields such as biological chemistry, biotechnology, medical science, pharmacy, natural product chemistry, organic synthesis, chemical industry, environment, agricultural, material with its high-recovery, high preparative capacibility and high accumulation ability.High-speed countercurrent chromatography is gentle and effectively separate and make it obtain using widely separating antibiotic field, is especially seeming very potential aspect the preparation microbiotic standard substance.
Adopting high speed adverse current chromatogram to separate in the research work of preparation erythromycin component, people such as Booth adopt high speed adverse current chromatogram at solvent systems to be: normal hexane: ethyl acetate: methyl alcohol: water=1.4: 2.0: 2.0: 1.0, theoretical plate number is not higher than separates the preparation Erythromycin A under 1219 the situation, obtained purity at the Erythromycin A more than 97% [1], [2], [3]([1]A.J.Booth,G.J.Lye.Optimization?of?the?fractionation?and?recovery?ofpolyketide?antibiotics?by?countercurrent?chromatography.J.Liq.Chromatogr.Rel.Technol.,2001,24(11&12):1841-1861
[2]A.J.Booth,I.A.Sutherland,G.J.Lye.Modeling?the?performance?of?pilot-scalecountercurrent?chromatography:Scale-up?predictions?and?experimental?verificationof?erythromycin?separation.Biotechnology?and?Bioengineering,2003,81(6):640-649
[3]A.J.Booth,S.H.Ngiam,G.J.Lye.Antibiotic?purification?from?fermentation?brothsby?counter-current?chromatography:analysis?of?product?purity?and?yield?trade-offs.Bioprocess?and?Biosystems?Engineering,2004,27:51-61)。
And have not yet to see the research report that adopts high speed adverse current chromatogram to separate preparation high purity berythromycin, C, domestic do not have highly purified berythromycin and Erythromycin C sample to provide as yet yet.
Summary of the invention
The purpose of this invention is to provide a kind of method that from the erythromycin raw material, prepares high purity Erythromycin A, berythromycin and Erythromycin C.Present method can prepare Erythromycin A, berythromycin and Erythromycin C at the same time or separately.
The present invention takes following technical scheme: a kind of method that adopts high speed adverse current chromatogram to prepare high purity Erythromycin A, berythromycin, Erythromycin C, comprise: the solvent system that constitutes stationary phase, moving phase by normal hexane, ethyl acetate, methyl alcohol, water preparation, on be stationary phase mutually, be moving phase mutually down, make in the whole cylinder of counter current chromatograph to be full of stationary phase, again moving phase is pumped in the post; The erythromycin raw material that will contain erythromycin component A, B, C is dissolved in the following phase solvent, by the sampling valve sample introduction, uv atlas difference receiving target component Erythromycin A, berythromycin, Erythromycin C according to detector, and carry out lyophilize, it is characterized in that the consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.5~1.3: 0.5~2.0 in the described solvent system: 0.5~2.0: 1.
Wherein, said erythromycin raw material is the erythromycin that Yueyang produces with connection pharmaceutcal corporation, Ltd, and product batch number is 20060710.
In above-mentioned solvent system, the consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.6~1.2: 1.0~2.0 in the described solvent system: 0.8~1.6: 1 o'clock, the purity of the Erythromycin A that obtains was up to 90%~100%;
The consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.6~1.2: 0.8~2.0 in the described solvent system: 0.8~1.6: 1 o'clock, the purity of the berythromycin that obtains was up to 80%~100%;
The consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.6~1.2: 1.0~2.0 in the described solvent system: 0.8~1.2: 1 o'clock, the purity of the Erythromycin C that obtains was up to 70%~95%.
The invention has the advantages that: 1. adopted the high speed adverse current chromatogram separation method in present method, high-speed countercurrent chromatography has been avoided the chemical modification because of the sample loss that adsorption causes, sample component, separation efficiency can be compared with preparation HPLC with capacity, and does not generally have the conditions of streaking at peak.2. when under described solvent systems, adopting high speed adverse current chromatogram to separate preparation Erythromycin A, berythromycin, Erythromycin C in the method, can prepare Erythromycin A, berythromycin, Erythromycin C as required at the same time or separately; 3, present method is separated preparation Erythromycin A, berythromycin, Erythromycin C, number of effective theoretical plates be 1300~2500, have separate efficient, fast, fractional dose big, sample free of losses, rate of recovery height, isolating environment gentleness, save characteristics such as solvent.
Embodiment
For better understanding the present invention, the invention will be further described below by embodiment, but for embodiment do not limit protection scope of the present invention:
Embodiment 1
Use half countercurrent chromatography instrument, be furnished with constant flow pump, the 15ml sampling valve, tetrafluoroethylene post, column volume are 200ml, the UV UV-detector.With volume ratio is 1.2: 2: 1.2: 1 normal hexane: ethyl acetate: methyl alcohol: water is miscible in separating funnel, shake up the back standing demix, get its upper solution (going up phase) and be stationary phase, lower floor's solution (following phase) is moving phase, behind the ultrasonic degas, earlier be full of whole cylinder with stationary phase, open high-speed counter-current chromatograph then, the adjustment engine speed is 900rpm, flow velocity with 1.3ml/min pumps into moving phase in the post, after treating that whole system is set up running balance, with the erythromycin raw material of 100mg be dissolved in 3ml following mutually in, by the sampling valve sample introduction, then according to the detector uv atlas, collect Erythromycin A respectively, berythromycin, the Erythromycin C component peaks, blow out organic solvent wherein, lyophilize, obtain white erythromycin solid, analyze through HPLC, Erythromycin A purity is 99.87%, and berythromycin purity is 92.09%, Erythromycin C purity is 90.24%, the number of effective theoretical plates that wherein separates Erythromycin A is 2116, and the number of effective theoretical plates that separates berythromycin is 1898, and the number of effective theoretical plates that separates Erythromycin C is 1764.
Embodiment 2
Use half countercurrent chromatography instrument, be furnished with constant flow pump, the 15ml sampling valve, tetrafluoroethylene post, column volume are 200ml, the UV UV-detector.With volume ratio is 0.6: 1.2: 1: 1 normal hexane: ethyl acetate: methyl alcohol: water is miscible in separating funnel, shake up the back standing demix, get its upper solution (going up phase) and be stationary phase, lower floor's solution (following phase) is moving phase, behind the ultrasonic degas, earlier be full of whole cylinder with stationary phase, open high-speed counter-current chromatograph then, the adjustment engine speed is 900rpm, flow velocity with 1.3ml/min pumps into moving phase in the post, after treating that whole system is set up running balance, with the erythromycin raw material of 100mg be dissolved in 3ml following mutually in, by the sampling valve sample introduction, then according to the detector uv atlas, collect Erythromycin A respectively, berythromycin, the Erythromycin C component peaks, blow out organic solvent wherein, lyophilize, obtain white erythromycin solid, analyze through HPLC, Erythromycin A purity is 99.61%, and berythromycin purity is 99.03%, Erythromycin C purity is 81.20%, the number of effective theoretical plates that wherein separates Erythromycin A is 1393, and the number of effective theoretical plates that separates berythromycin is 2401, and the number of effective theoretical plates that separates Erythromycin C is 1600.

Claims (4)

1. method that adopts high speed adverse current chromatogram to prepare high purity Erythromycin A, berythromycin, Erythromycin C, comprise: the solvent system that constitutes stationary phase, moving phase by normal hexane, ethyl acetate, methyl alcohol, water preparation, on be stationary phase mutually, be moving phase mutually down, make in the whole cylinder of counter current chromatograph to be full of stationary phase, again moving phase is pumped in the post; The erythromycin raw material that will contain erythromycin component A, B, C is dissolved in the following phase solvent, by the sampling valve sample introduction, uv atlas difference receiving target component Erythromycin A, berythromycin, Erythromycin C according to detector, and carry out lyophilize, it is characterized in that the consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.5~1.3: 0.5~2.0 in the described solvent system: 0.5~2.0: 1.
2. the method for preparing high purity Erythromycin A, berythromycin, Erythromycin C as claimed in claim 1, it is characterized in that the consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.6~1.2: 1.0~2.0 in the described solvent system: 0.8~1.6: 1.
3. the method for preparing high purity Erythromycin A, berythromycin, Erythromycin C as claimed in claim 1, it is characterized in that the consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.6~1.2: 0.8~2.0 in the described solvent system: 0.8~1.6: 1.
4. the method for preparing high purity Erythromycin A, berythromycin, Erythromycin C as claimed in claim 1, it is characterized in that the consumption volume ratio of normal hexane, ethyl acetate, methyl alcohol, water is 0.6~1.2: 1.0~2.0 in the described solvent system: 0.8~1.2: 1.
CNB2007100435179A 2007-07-06 2007-07-06 Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram Expired - Fee Related CN100509835C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2007100435179A CN100509835C (en) 2007-07-06 2007-07-06 Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2007100435179A CN100509835C (en) 2007-07-06 2007-07-06 Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram

Publications (2)

Publication Number Publication Date
CN101104631A true CN101104631A (en) 2008-01-16
CN100509835C CN100509835C (en) 2009-07-08

Family

ID=38998733

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2007100435179A Expired - Fee Related CN100509835C (en) 2007-07-06 2007-07-06 Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram

Country Status (1)

Country Link
CN (1) CN100509835C (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102093379A (en) * 2010-12-30 2011-06-15 上海同田生物技术有限公司 Preparation method of high-purity bergapten and psoralen
CN102127132A (en) * 2010-12-08 2011-07-20 华东理工大学 Method for preparing isovalerylspiramycin II and isovalerylspiramycin III
CN102863458A (en) * 2012-09-20 2013-01-09 福建省微生物研究所 Purification method of tacrolimus crude products
CN102924547A (en) * 2012-11-28 2013-02-13 宁夏启元药业有限公司 Purification method for erythromycin B pure product
CN103145722A (en) * 2013-03-05 2013-06-12 福建省微生物研究所 Method for separating and purifying epothilone by high-speed counter-current chromatography

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102127132A (en) * 2010-12-08 2011-07-20 华东理工大学 Method for preparing isovalerylspiramycin II and isovalerylspiramycin III
CN102093379A (en) * 2010-12-30 2011-06-15 上海同田生物技术有限公司 Preparation method of high-purity bergapten and psoralen
CN102093379B (en) * 2010-12-30 2015-08-05 上海同田生物技术股份有限公司 The preparation method of a kind of high purity bergapton and psoralene
CN102863458A (en) * 2012-09-20 2013-01-09 福建省微生物研究所 Purification method of tacrolimus crude products
CN102863458B (en) * 2012-09-20 2015-05-13 福建省微生物研究所 Purification method of tacrolimus crude products
CN102924547A (en) * 2012-11-28 2013-02-13 宁夏启元药业有限公司 Purification method for erythromycin B pure product
CN103145722A (en) * 2013-03-05 2013-06-12 福建省微生物研究所 Method for separating and purifying epothilone by high-speed counter-current chromatography

Also Published As

Publication number Publication date
CN100509835C (en) 2009-07-08

Similar Documents

Publication Publication Date Title
DeAmicis et al. Comparison of preparative reversed phase liquid chromatography and countercurrent chromatography for the kilogram scale purification of crude spinetoram insecticide
CN100509835C (en) Method for preparing erythromycin A, erythromycin B and erythromycin C by high speed adverse current chromatogram
CN102190646B (en) Method for preparing high-purity quercetagetin
CN100439384C (en) Method for separating preparing anthocyan monomer from mulberry
CN101864191B (en) Preparation method of high-purity monascus pigment component
CN102010387B (en) Method for purifying orlistat
CN101805352B (en) Method for preparing eriocalyxin B
CN101230080A (en) simulated moving bed chromatography separation of 20(S) and 20(R)-ginsenoside Rg3 enantiomer
CN101565437B (en) Separation and preparation method of patuletin-3-O-glucoside and astragalin
CN102381974A (en) Method for separating and preparing caffeic tannic acid from honeysuckle by utilizing high speed countercurrent chromatography
CN100427501C (en) Method for separating and preparing ursolic acid and its derivative from persimmon leaf using counter current chromatography
CN103145722B (en) A kind of method of high speed adverse current chromatogram separating-purifying ebormycine
CN108558983A (en) A kind of method that separation prepares four kinds of active materials of cycloartenyl ferulate
CN1136024C (en) Highspeed counter-current chromatographic separation process for preparing high purity catechin
CN106831943B (en) Method for purifying transdermal peptide at low cost
CN102167693B (en) Method for separating and preparing alpha-terthienyl, thianthrene and p-terphenyl
CN104974041B (en) High-purity chlorogenic acid and preparation method and application thereof
CN1176887C (en) Separating prepn process of carotenol
CN103570565B (en) Method for resolving fluoxetine through simulated moving bed chromatography
CN111018937A (en) Method for preparing soapberry saponin monomer by high-speed counter-current chromatography
CN101070335A (en) Process for preparing high-purity gentiopicrin
CN102952034A (en) Method for separating chiral compound metalaxyl by adopting simulated moving bed in fourth region
CN103193748A (en) Method for separating and preparing robinin monomer from wild chrysanthemum flowers
CN108409817A (en) A method of preparing Quercetin -3-D- xylosides and Quercetin -3-D- Arabinosides
CN1264822C (en) Process for preparing high purity huperzine A

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090708

Termination date: 20130706